BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 18494806)

  • 1. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y; Guo XH; Vaz JA;
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
    Khutsoane D; Sharma SK; Almustafa M; Jang HC; Azar ST; Danciulescu R; Shestakova M; Ayad NM; Guler S; Bech OM;
    Diabetes Obes Metab; 2008 Mar; 10(3):212-22. PubMed ID: 18269636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.
    Strojek K; Bebakar WM; Khutsoane DT; Pesic M; Smahelová A; Thomsen HF; Kalra S
    Curr Med Res Opin; 2009 Dec; 25(12):2887-94. PubMed ID: 19821654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W; Ji Q; Zhu D; Yang J; Chen L; Liu Z; Yu D; Yan L
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
    Valensi P; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Wenying Y;
    Int J Clin Pract; 2009 Mar; 63(3):522-31. PubMed ID: 19187170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE study.
    Dornhorst A; Lüddeke HJ; Sreenan S; Kozlovski P; Hansen JB; Looij BJ; Meneghini L;
    Int J Clin Pract; 2008 Apr; 62(4):659-65. PubMed ID: 18324957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes.
    Bebakar WM; Chow CC; Kadir KA; Suwanwalaikorn S; Vaz JA; Bech OM;
    Diabetes Obes Metab; 2007 Sep; 9(5):724-32. PubMed ID: 17593237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
    Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L
    Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study.
    Shestakova M; Sharma SK; Almustafa M; Min KW; Ayad N; Azar ST; Danciulescu R; Khutsoane D; Guler S
    Curr Med Res Opin; 2007 Dec; 23(12):3209-14. PubMed ID: 18005503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study.
    Yang W; Gao Y; Liu G; Chen L; Fu Z; Zou D; Feng P; Zhao Z
    Curr Med Res Opin; 2010 Jan; 26(1):101-7. PubMed ID: 19916705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study design and baseline characteristics of patients in the PRESENT study.
    Shestakova M; Bech OM; Momani MS
    Diabetes Res Clin Pract; 2008 Sep; 81 Suppl 1():S3-9. PubMed ID: 18672309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
    Dashora U; Ashwell SG; Home PD
    Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients.
    Pala L; Mannucci E; Dicembrini I; Rotella CM
    Diabetes Res Clin Pract; 2007 Oct; 78(1):132-5. PubMed ID: 17445933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.